S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)

Protara Therapeutics (TARA) Stock Price, News & Analysis

$1.64
+0.05 (+2.81%)
(As of 10:40 AM ET)
Compare
Today's Range
$1.60
▼
$1.78
50-Day Range
$1.10
▼
$1.76
52-Week Range
$1.04
▼
$4.18
Volume
82,092 shs
Average Volume
31,136 shs
Market Capitalization
$18.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Protara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,261.0% Upside
$23.00 Price Target
Short Interest
Healthy
0.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.54) to ($3.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

612th out of 942 stocks

Biological Products, Except Diagnostic Industry

96th out of 157 stocks

See Top Rated MarketRank™ Stocks Here

TARA stock logo

About Protara Therapeutics Stock (NASDAQ:TARA)

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

TARA Stock Price History

TARA Stock News Headlines

December 2, 2023 | markets.businessinsider.com
Oppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)
November 30, 2023 | finance.yahoo.com
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
December 11, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
November 5, 2023 | benzinga.com
Protara Therapeutics Stock (NASDAQ:TARA) Earnings Dates and Earning Calls
November 5, 2023 | msn.com
Protara Therapeutics reports Q3 results
November 3, 2023 | msn.com
Protara Therapeutics files for $300M mixed shelf
November 3, 2023 | finance.yahoo.com
Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results
November 3, 2023 | finance.yahoo.com
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
December 11, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 24, 2023 | msn.com
Protara begins dosing in Phase II lymphatic malformation cell therapy trial
October 23, 2023 | finance.yahoo.com
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
October 7, 2023 | benzinga.com
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
September 10, 2023 | finance.yahoo.com
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
September 5, 2023 | finance.yahoo.com
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 4, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)
August 4, 2023 | msn.com
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation
August 3, 2023 | msn.com
Protara Therapeutics (TARA) Price Target Decreased by 6.96% to 32.03
August 3, 2023 | finance.yahoo.com
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
July 14, 2023 | finance.yahoo.com
TARA - Protara Therapeutics, Inc.
June 11, 2023 | finance.yahoo.com
US74365U1079.SG - Protara Therapeutics Inc.
May 25, 2023 | markets.businessinsider.com
H.C. Wainwright Remains a Buy on Kamada (KMDA)
May 17, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Bellerophon (BLPH)
May 8, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Keros Therapeutics (KROS)
May 8, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Viking Therapeutics (VKTX)
May 4, 2023 | msn.com
Recap: Protara Therapeutics Q1 Earnings
May 4, 2023 | finance.yahoo.com
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
May 2, 2023 | finance.yahoo.com
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
See More Headlines
Receive TARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/13/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TARA
CUSIP
N/A
CIK
1359931
Web
www.proteontherapeutics.com
Phone
(646) 844-0337
Fax
781-487-6729
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$23.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+1,261.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,950,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.17%
Return on Assets
-39.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.48
Quick Ratio
11.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.06 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
11,365,000
Free Float
9,274,000
Market Cap
$19.21 million
Optionable
Not Optionable
Beta
1.19
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Jesse Shefferman (Age 51)
    Co-Founder, CEO, President & Director
    Comp: $1.11M
  • Dr. Jacqueline Zummo M.B.A. (Age 42)
    M.P.H., Ph.D., Co-Founder, Senior VP & Chief Scientific Operations Officer
    Comp: $743.68k
  • Dr. Jathin Bandari M.D. (Age 36)
    Chief Medical Officer
    Comp: $687.86k
  • Mr. Patrick Fabbio M.B.A. (Age 55)
    Chief Financial Officer
  • Ms. Hannah Fry (Age 32)
    VP, Principal Accounting Officer & Controller
  • Ms. Justine O'Malley
    Senior Vice President of Investor Relations & Corporate Affairs
  • Ms. Mary J. Grendell
    General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions














TARA Stock Analysis - Frequently Asked Questions

Should I buy or sell Protara Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARA shares.
View TARA analyst ratings or view top-rated stocks.

What is Protara Therapeutics' stock price target for 2024?

1 brokerages have issued 12 month price targets for Protara Therapeutics' shares. Their TARA share price targets range from $23.00 to $23.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 1,261.0% from the stock's current price.
View analysts price targets for TARA or view top-rated stocks among Wall Street analysts.

How have TARA shares performed in 2023?

Protara Therapeutics' stock was trading at $2.68 at the beginning of 2023. Since then, TARA stock has decreased by 36.9% and is now trading at $1.6899.
View the best growth stocks for 2023 here.

When is Protara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our TARA earnings forecast.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) announced its earnings results on Friday, November, 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.23.

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX), Trevena (TRVN), AIM ImmunoTech (AIM), Chimerix (CMRX), CTI BioPharma (CTIC), Fortress Biotech (FBIO), Genocea Biosciences (GNCA) and Otonomy (OTIC).

Who are Protara Therapeutics' major shareholders?

Protara Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jesse Shefferman, Luke M Beshar, Martin Sebastian Olivo and Opaleye Management Inc.
View institutional ownership trends.

How do I buy shares of Protara Therapeutics?

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TARA) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -